BGPT: Author Review: Xiaojuan Yang

Fuel Your Discoveries

Quick Explanation Copied

Xiaojuan Yang — evidence-based critique

Based on the provided record(s), Yang’s output spans multiple biomedical subareas and includes at least some work with multi-omics / mechanistic claims (e.g., CRISPR-based diatom N-glycosylation editing). However, the dataset you provided also includes non-biology engineering/CS/other domains and even a “retracted article” entry, which creates major identity/field-attribution risk for “Xiaojuan Yang” as a single person.

Key caution: author-name ambiguity + retraction + mostly-review/non-primary entries implies we can’t confidently assess *biological scientific rigor* across the whole publication record from what’s shown.

Long Explanation

Author Review: Xiaojuan Yang (critical, evidence-focused)

Date context: Apr 29, 2026.

Identity & field risk (high): The supplied OpenAlex matches include multiple similarly named researchers (e.g., “Xia Yang”, “Xiao‐Juan Yang”, “Xiaojuan Yang”) with very different citation profiles. Your provided “papers” list also contains non-biological engineering/CS titles. This makes it difficult to determine whether all entries correspond to the same biological scientist.

Paper-level quality/nterms across the provided 4 papers (from your dataset)

Signal extraction from what you provided (review vs experimental)

1) What can be said about scientific strength from the provided evidence

A. Evidence of mechanistic/experimental depth in at least one record
The diatom N-glycosylation work includes CRISPR/Cas9 knockout and overexpression, Golgi-associated localization, protein–protein interaction testing, and N-glycoproteomics via LC-MS/MS with multiple analysis tools. Those elements are consistent with a more rigorous mechanistic workflow than a narrative review. Evidence is contained in your provided excerpt for .

B. Evidence of topical breadth—but also variability in evidentiary level
Two other provided items are explicitly narrative reviews (ubiquitin/deubiquitin signaling and dispersant-based nanoparticles for biofilm reinfection). Narrative reviews can be useful for synthesis, but they are not the same as new experimental demonstrations; they also often inherit publication-selection bias and uneven coverage. Your excerpts for those papers support this “review” classification and mention biases/limitations (e.g., selection and uneven representation). See and .

C. Experimental work in materials/fluorescent probes exists in the subset
The carbon dot synthesis paper reports low-temperature synthesis from pumpkin, characterization (TEM/FTIR/XPS/UV-vis/PL), and in vitro/in vivo biological testing (MCF-7 and zebrafish) in your excerpt. This indicates experimental capability, but it also means the overall “biological merit” depends heavily on whether the same Xiaojuan Yang is responsible across domains. See .

2) Critical risks & scientific blind spots (what would weaken confidence)

Risk 1 — Name disambiguation / author identity ambiguity (major)

Your provided OpenAlex matches show multiple distinct “Xiaojuan/Xia Yang” profiles with very different h-index/citation counts. Separately, your provided “papers” list contains non-biological titles. Without a unique identifier (ORCID, institutional affiliation, consistent topic clustering), any attempt to judge “Yang’s biological scientific strength” risks conflating multiple people.

Risk 2 — Retraction entry present in your supplied list

Your dataset includes a “RETRACTED ARTICLE” on haplotype analysis and breast cancer risk. Even if retractions occur for various reasons, retraction is a strong negative signal for reliability of at least some parts of the record. Your excerpt labels the article as retracted and provides study context and limitations. Your retracted entry itself is described as: .

Note: the citation for the retracted entry lacks a DOI in your provided block, so I cannot provide a DOI-formatted citation per your strict citation rules.

Risk 3 — Review papers don’t directly test hypotheses

The ubiquitination and nanoparticle biofilm pieces are narrative reviews (per your excerpt). They may still be high-quality academically, but they do not provide new causal estimates. Overreliance on review-style entries would lower confidence in “original experimental rigor.”

Risk 4 — Reproducibility & data availability constraints

Your extracted fields report that at least one work is review-based with “no datasets generated,” and that some data are “available upon request.” For the diatom glycosylation paper, your excerpt also indicates data availability via request rather than guaranteed deposition (even though supplementary material exists). .

3) What I would conclude (with explicit confidence)

Conclusion (narrowly grounded in the provided subset): Within the limited set of four provided DOI-linked items, there is evidence of both (i) mechanistic/experimental biological research (diatom CRISPR + glycoproteomics) and (ii) additional experimental capability in bioimaging/sensing materials, alongside narrative review contributions. However, the overall “scientific strength” of “Xiaojuan Yang” as a biological scientist cannot be confidently generalized because the provided author record includes strong identity ambiguity and at least one retracted-entry complication.

Confidence level: low-to-moderate (main limitation is identity disambiguation + incomplete bibliographic linkage for the retracted item).

Helpful next step (to improve validity)

If you paste the author’s ORCID (or the exact OpenAlex author ID you mean), I can re-run the analysis with strict author identity resolution and produce a more reliable, field-specific rigor score.

Rigor vs evidence type (review vs experimental) using provided scores

BGPT link-outs (bespoke follow-ups)

Feedback:

Updated: April 29, 2026